RU2312864C2 - Новые соединения конденсированного имидазола, обладающие свойствами агонистов рецептора св2 - Google Patents

Новые соединения конденсированного имидазола, обладающие свойствами агонистов рецептора св2 Download PDF

Info

Publication number
RU2312864C2
RU2312864C2 RU2003129638/04A RU2003129638A RU2312864C2 RU 2312864 C2 RU2312864 C2 RU 2312864C2 RU 2003129638/04 A RU2003129638/04 A RU 2003129638/04A RU 2003129638 A RU2003129638 A RU 2003129638A RU 2312864 C2 RU2312864 C2 RU 2312864C2
Authority
RU
Russia
Prior art keywords
alkyl
group
mmol
methyl
cyclopropylmethyl
Prior art date
Application number
RU2003129638/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2003129638A (ru
Inventor
Юн-Ксинг ЧЕНГ (CA)
Юн-Ксинг ЧЕНГ
Мирослав ТОМАШЕВСКИ (CA)
Мирослав Томашевски
Кристофер УОЛПОЛ (CA)
Кристофер Уолпол
Хьюэй ЯНГ (CA)
Хьюэй ЯНГ
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2003129638A publication Critical patent/RU2003129638A/ru
Application granted granted Critical
Publication of RU2312864C2 publication Critical patent/RU2312864C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
RU2003129638/04A 2001-04-20 2002-04-18 Новые соединения конденсированного имидазола, обладающие свойствами агонистов рецептора св2 RU2312864C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101387A SE0101387D0 (sv) 2001-04-20 2001-04-20 Novel compounds
SE0101387-9 2001-04-20

Publications (2)

Publication Number Publication Date
RU2003129638A RU2003129638A (ru) 2005-04-10
RU2312864C2 true RU2312864C2 (ru) 2007-12-20

Family

ID=20283822

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003129638/04A RU2312864C2 (ru) 2001-04-20 2002-04-18 Новые соединения конденсированного имидазола, обладающие свойствами агонистов рецептора св2

Country Status (25)

Country Link
US (2) US7030139B2 (enExample)
EP (1) EP1390350A1 (enExample)
JP (1) JP2004528334A (enExample)
KR (1) KR20040022421A (enExample)
CN (1) CN1250531C (enExample)
AR (1) AR035959A1 (enExample)
BG (1) BG108271A (enExample)
BR (1) BR0208907A (enExample)
CA (1) CA2444381A1 (enExample)
CZ (1) CZ20032833A3 (enExample)
EE (1) EE200300524A (enExample)
HU (1) HUP0303825A3 (enExample)
IL (1) IL158142A0 (enExample)
IS (1) IS6971A (enExample)
MX (1) MXPA03009558A (enExample)
MY (1) MY134568A (enExample)
NO (1) NO20034665L (enExample)
NZ (1) NZ528403A (enExample)
PL (1) PL366517A1 (enExample)
RU (1) RU2312864C2 (enExample)
SE (1) SE0101387D0 (enExample)
SK (1) SK13032003A3 (enExample)
UA (1) UA76743C2 (enExample)
WO (1) WO2002085866A1 (enExample)
ZA (1) ZA200307752B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487436A4 (en) 2002-03-08 2009-06-03 Signal Pharm Inc POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS
SE0203070D0 (en) * 2002-10-16 2002-10-16 Astrazeneca Ab Novel compounds
EP1608628A2 (en) * 2003-03-17 2005-12-28 Takeda San Diego, Inc. Histone deacetylase inhibitors
SE0300908D0 (sv) * 2003-03-31 2003-03-31 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
SE0301701D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301698D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301699D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
DK1637527T3 (da) * 2003-06-26 2013-07-01 Takeda Pharmaceutical Cannabinoid receptor modulator.
US7157471B2 (en) * 2003-08-25 2007-01-02 Boehringer Ingelheim International Gmbh Haloalkyl- and piperidine-substituted benzimidazole-derivatives
WO2005021547A2 (en) * 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
SE0302573D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302571D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
JP2007509072A (ja) * 2003-10-16 2007-04-12 キャラ セラピューティックス， インコーポレイテッド アミドまたはチオアミド誘導体および疼痛の処置におけるその使用方法
EP1797074A4 (en) * 2004-09-24 2009-04-01 Astrazeneca Ab COMPOUNDS, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND APPLICATIONS THEREOF IIII
JP2008514594A (ja) * 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体及びカンナビノイド受容体リガンドとしてのその使用ｉ
WO2006033631A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i
UA87327C2 (ru) * 2004-09-24 2009-07-10 Астразенека Аб Производные бензимидазола, композиция, которая их содержит, их получение и применение
JP2008514590A (ja) * 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体、それを含む組成物、その製造方法及びその使用
JP2008514591A (ja) * 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体及びカンナビノイド受容体リガンドとしてのその使用
AU2005287426A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof III
BRPI0515897A (pt) * 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
AU2005287429A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparations thereof and uses thereof II
CN101048382B (zh) * 2004-10-27 2010-05-05 霍夫曼-拉罗奇有限公司 新型吲哚或苯并咪唑衍生物
ATE417830T1 (de) * 2004-11-02 2009-01-15 Pfizer Sulfonylbenzimidazolderivate
SE0402763D0 (sv) * 2004-11-11 2004-11-11 Astrazeneca Ab Nitro indazole derivatives
SE0402762D0 (sv) * 2004-11-11 2004-11-11 Astrazeneca Ab Indazole sulphonamide derivatives
US8138177B2 (en) 2005-03-15 2012-03-20 Pfizer Inc. Benzimidazolone derivatives as CB2 receptor ligands
JP2008539246A (ja) 2005-04-28 2008-11-13 フェリング ベスローテン フェンノートシャップ Ｉｂｄ治療のための新規化合物の使用
AR058705A1 (es) 2005-12-23 2008-02-20 Astrazeneca Ab Compuestos de bencimidazol como inhibidores del receptor vaniloide 1 (vr1)
WO2007091950A1 (en) * 2006-02-07 2007-08-16 Astrazeneca Ab Benzimidazoles and imidazopyridines useful in the treatment of diseases or disorders associated with cannabinoid receptor 2 (cb2) such as pain
EP1994011B1 (en) 2006-03-06 2010-10-13 RaQualia Pharma Inc Sulfonyl benzimidazole derivatives
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) * 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
TW200808772A (en) * 2006-06-13 2008-02-16 Astrazeneca Ab Therapeutic compounds
ES2341188T3 (es) 2006-07-04 2010-06-16 Janssen Pharmaceutica Nv Agonistas de cannabinoides de bencimidazol que llevan un grupo heterociclico sustituido.
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
FR2907784B1 (fr) * 2006-10-27 2009-02-13 Sod Conseils Rech Applic Derives phenyliques et leur utilisation comme medicament
WO2009116074A2 (en) * 2008-02-13 2009-09-24 Cadila Healthcare Limited Substituted benzimidazoles as cannabinoid modulator
US20120277296A1 (en) 2009-07-23 2012-11-01 Sophie Lotersztajn Selective CB2 Receptor Agonists for Use in the Prevention or Treatment of Alcoholic Liver Disease
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
WO2011103018A1 (en) 2010-02-18 2011-08-25 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US8759535B2 (en) * 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US9181226B2 (en) 2011-07-18 2015-11-10 Merck Patent Gmbh Benzamides
CN102977056B (zh) * 2012-11-28 2014-11-26 深圳万乐药业有限公司 N-苄氧羰基-3-氟-4-吗啉基苯胺的合成方法
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
WO2017157332A1 (zh) * 2016-03-18 2017-09-21 江苏恒瑞医药股份有限公司 芳香酰胺类衍生物、其制备方法及其在医药上的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018616A2 (en) * 1994-01-03 1995-07-13 Acea Pharm Inc 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
RU97100643A (ru) * 1994-06-10 1999-02-20 Бык Гульден Ломберг Хемише Фабрик Гмбх Тиопиридины для борьбы с бактериями helicobacter

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2945044A (en) * 1957-07-12 1960-07-12 Ciba Pharm Prod Inc Certain 1-(diethyl-aminoethyl), 5-amino, 2-benzyl or substituted benzyl, benzimidazoles
FR1481049A (fr) 1965-11-25 1967-05-19 France Ministre Des Armees Nouveaux dialkylaminoalkyl-1 p-alkoxyphényl alkyl-2 benzimidazoles 5-substitués
US6107312A (en) * 1994-06-10 2000-08-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiopyridines for use in the control of helicobacter bacteria
SE0203070D0 (en) * 2002-10-16 2002-10-16 Astrazeneca Ab Novel compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018616A2 (en) * 1994-01-03 1995-07-13 Acea Pharm Inc 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
US5620978A (en) * 1994-01-03 1997-04-15 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor
RU97100643A (ru) * 1994-06-10 1999-02-20 Бык Гульден Ломберг Хемише Фабрик Гмбх Тиопиридины для борьбы с бактериями helicobacter

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAI SUI XIONG et al. 5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones:Novel, Systemically Active and Broad Spectrum Antagonists for NMDA/glycine, AMPA, and Kainate Receptors J. of Medicinal Chemisry (English) 1997, 40(22), 3679-3686). PADLIETTI G. et al. Dialkylaminoalkylbenzimidazoles of pharmacological interest Farmaco, Edizione Scientifica(Italian), 1972, 27(4), 333-42; Chem.Abstr. v.77, №7, ref.48338. LECOLIER SERGE et al. New benzimidazoles with morphine activity, Chim Ther., 1967, v.2, №1, p.16-24. *
GRELLA GIUSEPPE et al. Synthesis and choleretic activity of 3-[2-(3-R',4-R''-5-R'''-benzyl)-5-R-benzimidazol-1-y1]butanoic acids, Farmaco (English), 1992, 47(1), 21-35. IGNACZAK WOJCIECH et al. 1,2-Diamino-4-nitrobensene synthesis Przemisl Chemiczny, 1986, 65(9), 475-76). *

Also Published As

Publication number Publication date
HUP0303825A3 (en) 2005-06-28
HUP0303825A2 (hu) 2004-03-01
WO2002085866A1 (en) 2002-10-31
US20040116465A1 (en) 2004-06-17
UA76743C2 (uk) 2006-09-15
PL366517A1 (en) 2005-02-07
US7030139B2 (en) 2006-04-18
CN1250531C (zh) 2006-04-12
BG108271A (bg) 2004-12-30
MY134568A (en) 2007-12-31
SK13032003A3 (sk) 2005-01-03
SE0101387D0 (sv) 2001-04-20
RU2003129638A (ru) 2005-04-10
CA2444381A1 (en) 2002-10-31
NZ528403A (en) 2005-05-27
EP1390350A1 (en) 2004-02-25
NO20034665D0 (no) 2003-10-17
AR035959A1 (es) 2004-07-28
IL158142A0 (en) 2004-03-28
JP2004528334A (ja) 2004-09-16
US20060135554A1 (en) 2006-06-22
MXPA03009558A (es) 2004-02-12
IS6971A (is) 2003-09-29
CZ20032833A3 (en) 2004-05-12
BR0208907A (pt) 2004-04-20
ZA200307752B (en) 2005-01-03
EE200300524A (et) 2004-02-16
KR20040022421A (ko) 2004-03-12
CN1503787A (zh) 2004-06-09
NO20034665L (no) 2003-12-10

Similar Documents

Publication Publication Date Title
RU2312864C2 (ru) Новые соединения конденсированного имидазола, обладающие свойствами агонистов рецептора св2
US4996224A (en) 1-benzyl-4- or 5-pyrrolidinomethyl-pyrrolidin-2-ones and nootropic method of use thereof
DE69413523T2 (de) Benzimidazole derivate
EP1771441B1 (de) Neue carbonsäureamide als faktor xa-inhibitoren
DE19955794A1 (de) Pyrrolidin-Derivate-CCR-3-Rezeptor-Antagonisten
WO2001032649A1 (de) Arylalkane, arylalkene und aryl-azaalkane, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP1100795A1 (de) Disubstituierte bicyclische heterocyclen mit insbesondere eine thrombinhemmende wirkung
MXPA06013538A (es) Compuestos terapeuticos: piridina como soporte.
NZ230068A (en) Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions
DE602004011204T2 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
US7407968B2 (en) Compounds
DE19939463A1 (de) Aminocarbonyl-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2007025940A1 (de) Substituierte biaryle und deren verwendung als faktor xa-inhibitoren
DE60224723T2 (de) Therapeutische heterocyclen als bradykinin b2 rezeptor antagonisten
JP2007506722A (ja) ベンゾイミダゾール誘導体、それを含む組成物、その製造およびその使用
DE19718181A1 (de) Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
AU2002307586A1 (en) Novel compounds
EP1220844B1 (de) Arylsulfonamid-substituierte benzimidazolderivate und ihre verwendung als tryptase-inhibitoren
EP1220845B1 (de) Arylsulfonamid-substituierte benzimidazolderivate ihre verwendung als tryptase-inhibitoren
DE19945787A1 (de) Arylsulfonamid-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10105628A1 (de) Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
NZ538692A (en) Chemical process involving selective reduction of a nitro moiety
DE102004060984A1 (de) Neue Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
MX2007003121A (es) Derivados de bencimidazol, compuestos, composiciones que los contienen, preparacion y usos de los mismos ii.
DE10144658A1 (de) Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20080419